News
ABSCF
11.90
NaN%
--
AB Science Reports Key Developments and Financial Results
Barchart · 10/11 22:58
Ab Science’s Phase 3 ALS Trial: A Key Development for Investors
TipRanks · 10/03 16:31
Analysts Are Bullish on Top Healthcare Stocks: AB Science SA (ABSCF), Gilead Sciences (GILD)
TipRanks · 10/02 12:20
Weekly Report: what happened at ABSCF last week (0908-0912)?
Weekly Report · 09/15 09:27
Weekly Report: what happened at ABSCF last week (0901-0905)?
Weekly Report · 09/08 09:28
Weekly Report: what happened at ABSCF last week (0825-0829)?
Weekly Report · 09/01 09:26
Weekly Report: what happened at ABSCF last week (0818-0822)?
Weekly Report · 08/25 09:29
Weekly Report: what happened at ABSCF last week (0811-0815)?
Weekly Report · 08/18 09:27
Weekly Report: what happened at ABSCF last week (0804-0808)?
Weekly Report · 08/11 09:28
Weekly Report: what happened at ABSCF last week (0728-0801)?
Weekly Report · 08/04 09:30
Weekly Report: what happened at ABSCF last week (0721-0725)?
Weekly Report · 07/28 09:29
Weekly Report: what happened at ABSCF last week (0714-0718)?
Weekly Report · 07/21 09:28
Weekly Report: what happened at ABSCF last week (0707-0711)?
Weekly Report · 07/14 09:29
Weekly Report: what happened at ABSCF last week (0630-0704)?
Weekly Report · 07/07 09:28
Weekly Report: what happened at ABSCF last week (0623-0627)?
Weekly Report · 06/30 09:29
Weekly Report: what happened at ABSCF last week (0616-0620)?
Weekly Report · 06/23 09:27
Weekly Report: what happened at ABSCF last week (0609-0613)?
Weekly Report · 06/16 09:29
Weekly Report: what happened at ABSCF last week (0602-0606)?
Weekly Report · 06/09 09:29
Weekly Report: what happened at ABSCF last week (0526-0530)?
Weekly Report · 06/02 09:31
More
Webull provides a variety of real-time ABSCF stock news. You can receive the latest news about Ab Science through multiple platforms. This information may help you make smarter investment decisions.
About ABSCF
AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.